Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Entera Bio Ltd. Ordinary Shares

ENTX

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Last trade $3.02
Day change $0.00 (0.00%)
Day range $2.92 – $3.10
Volume 97,414
Market cap $526M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$525.9M
Price / earnings
—
Price / book
1.92×
Price / sales
—
EV / sales
—
EV / EBITDA
-14.17×

Profitability

Earnings per share
-$0.17
Return on assets
-10.62%
Return on equity
-10.73%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
128.41×
Quick ratio
128.41×
Cash ratio
123.49×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.84M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ENTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$42K$82K
Cost of revenue$0$0$0$0$0$0$42K$82K
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.34M$1.36M$1.29M$1.32M$1.61M$1.15M$1.44M$1.14M
Research and development$4.93M$3.2M$2.25M$1.72M$1.64M$1.52M$1.12M$1.2M
Total operating expenses$7.27M$4.56M$3.54M$3.04M$3.26M$2.67M$2.56M$2.34M
Operating income-$7.27M-$4.56M-$3.54M-$3.04M-$3.26M-$2.67M-$2.56M-$2.34M
Interest expense$0-$2.75M$0$0$0$12K$0$0
Income before taxes-$15.6M-$7.31M-$3.51M-$3.02M-$3.2M-$2.66M-$2.57M-$2.34M
Income taxes$0$0$0$0$0$0$0$14K
Net income-$15.6M-$7.31M-$3.51M-$3.02M-$3.2M-$2.66M-$2.57M-$2.36M
Net income attributable to common shareholders-$15.6M-$7.31M-$3.51M-$3.02M-$3.2M-$2.66M-$2.57M-$2.36M
EBITDA-$7.26M-$4.55M-$3.53M-$3.04M-$3.25M-$2.66M-$2.56M-$2.33M
Basic earnings per share-$0.11-$0.14-$0.07-$0.06-$0.07-$0.06-$0.06-$0.06
Diluted earnings per share-$0.11-$0.14-$0.07-$0.06-$0.07-$0.06-$0.06-$0.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biopharmaceutical company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is advancing its lead candidate EB613 (oral PTH(1-34)) for osteoporosis treatment, which met primary and secondary endpoints in a Phase 2 study, with positive FDA feedback received on planned Phase 3 registrational studies.

GlobeNewswire Inc.

Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market

Entera Bio received positive FDA feedback on its Phase 3 protocol for EB613, an oral osteoporosis tablet based on teriparatide. The FDA accepted the company's proposed single-study registrational strategy with approximately 750 postmenopausal women, using total hip bone mineral density at 12 months as the primary endpoint. Phase 3 is expected to initiate in late 2026 with topline results anticipated in H2 2028. The approval could represent the first oral anabolic osteoporosis treatment, addressing a market where injectable therapies have limited adoption despite high efficacy.

Benzinga

Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)

U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump suggested the U.S. could seize Iran's oil infrastructure while characterizing Iran's new leaders as 'very reasonable.' Markets are pricing in a 96.4% likelihood of unchanged Fed rates in April. Key movers include Palantir Technologies, Rezolve AI, and Entera Bio, while analyst Mohamed El-Erian warns of 'stagflationary winds' and economic headwinds ahead.

Benzinga

Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In Focus

U.S. stock futures rose on Monday following Friday's sharp sell-off, with major indices recovering from correction territory. President Trump's comments about Iran's new leaders being 'very reasonable' and potential oil agreements provided some market optimism. Key movers included Palantir (partnership expansion), Rezolve AI (raised revenue outlook), and Entera Bio (earnings miss). Analysts warn of 'stagflationary winds' and expect continued volatility ahead.

GlobeNewswire Inc.

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

OPKO Health will report its financial results for Q4 and full year 2025 on February 26, 2026, followed by a conference call. The company has also expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet for hypoparathyroidism treatment, marking the third successful program combining Entera's N-Tab platform with OPKO's protein chemistry capabilities.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.